XML 15 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Statements of Equity - USD ($)
$ in Thousands
Total
Total Lisata Therapeutics, Inc. Stockholders' Equity
Series B Convertible Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Treasury Stock
Non- Controlling Interest in Subsidiary
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Preferred stock, shares outstanding     0            
Beginning balance at Dec. 31, 2020 $ 32,242 $ 32,496 $ 0 $ 1 $ 458,766 $ (13) $ (425,550) $ (708) $ (254)
Common stock, beginning balance (in shares) at Dec. 31, 2020       1,292,000          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net loss (20,672) (20,672)         (20,672)    
Share-based compensation (in shares)       36,000          
Share-based compensation 1,391 1,391     1,391        
Net proceeds from issuances of common stock 85,479 85,479   $ 3 85,476        
Net proceeds from issuance of common stock and warrants (in shares)       2,658,000          
Proceeds from option exercises 24 24     24        
Unrealized loss on marketable securities (51) (51)       (51)      
Preferred stock, ending balance (in shares) at Sep. 30, 2021     0            
Common stock, ending balance (in shares) at Sep. 30, 2021       3,986,000          
Ending balance at Sep. 30, 2021 98,413 98,667 $ 0 $ 4 545,657 (64) (446,222) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Preferred stock, shares outstanding     0            
Beginning balance at Jun. 30, 2021 104,679 104,933 $ 0 $ 4 544,949 (17) (439,295) (708) (254)
Common stock, beginning balance (in shares) at Jun. 30, 2021       3,967,000          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net loss (6,927) (6,927)         (6,927)    
Share-based compensation (in shares)       19,000          
Share-based compensation 708 708     708        
Unrealized loss on marketable securities (47) (47)       (47)      
Preferred stock, ending balance (in shares) at Sep. 30, 2021     0            
Common stock, ending balance (in shares) at Sep. 30, 2021       3,986,000          
Ending balance at Sep. 30, 2021 $ 98,413 98,667 $ 0 $ 4 545,657 (64) (446,222) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Preferred stock, shares outstanding     0            
Preferred stock, shares outstanding 10,000   0            
Beginning balance at Dec. 31, 2021 $ 92,000 92,254 $ 0 $ 4 546,044 (70) (453,016) (708) (254)
Common stock, beginning balance (in shares) at Dec. 31, 2021 3,985,981     3,986,000          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net loss $ (48,235) (48,235)         (48,235)    
Share-based compensation (in shares)       100,000          
Share-based compensation 1,899 1,899   $ 0 1,899        
Net proceeds from issuances of common stock 29 29     29        
Issuance of common stock in connection with Merger (in shares)       3,773,000          
Issuance of common stock in connection with merger 26,098 26,098   $ 4 26,094        
Net proceeds from issuance of common stock and warrants (in shares)       4,000          
Unrealized loss on marketable securities 5 5       5      
Foreign currency translation adjustment $ (25)         (25)      
Preferred stock, ending balance (in shares) at Sep. 30, 2022 10,000   0            
Common stock, ending balance (in shares) at Sep. 30, 2022 7,862,602     7,863,000          
Ending balance at Sep. 30, 2022 $ 71,771 72,025 $ 0 $ 8 574,066 (90) (501,251) (708) (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Preferred stock, shares outstanding     0            
Beginning balance at Jun. 30, 2022 82,137 82,391 $ 0 $ 4 547,032 (70) (463,868) (708) (254)
Common stock, beginning balance (in shares) at Jun. 30, 2022       4,038,000          
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Net loss (37,383) (37,383)         (37,383)    
Share-based compensation (in shares)       52,000          
Share-based compensation 939 939     940        
Issuance of common stock in connection with Merger (in shares)       3,773,000          
Issuance of common stock in connection with merger 26,098 26,098   $ 4 26,094        
Unrealized loss on marketable securities 5 5       5      
Foreign currency translation adjustment $ (25)         (25)      
Preferred stock, ending balance (in shares) at Sep. 30, 2022 10,000   0            
Common stock, ending balance (in shares) at Sep. 30, 2022 7,862,602     7,863,000          
Ending balance at Sep. 30, 2022 $ 71,771 $ 72,025 $ 0 $ 8 $ 574,066 $ (90) $ (501,251) $ (708) $ (254)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Preferred stock, shares outstanding 10,000   0